Lyell Wealth Management LP Has $1.06 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Lyell Wealth Management LP trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 13.9% in the first quarter, HoldingsChannel reports. The firm owned 6,405 shares of the company’s stock after selling 1,034 shares during the period. Lyell Wealth Management LP’s holdings in Johnson & Johnson were worth $1,062,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Northern Trust Corp lifted its stake in shares of Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock valued at $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Invesco Ltd. lifted its position in shares of Johnson & Johnson by 6.5% during the fourth quarter. Invesco Ltd. now owns 19,126,079 shares of the company’s stock valued at $2,766,014,000 after purchasing an additional 1,171,975 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Johnson & Johnson by 2.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock valued at $3,031,955,000 after purchasing an additional 448,666 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Johnson & Johnson by 4.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 14,773,493 shares of the company’s stock valued at $2,136,390,000 after purchasing an additional 636,430 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $167.31 on Thursday. The company’s 50 day moving average is $156.93 and its 200-day moving average is $156.30. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $402.94 billion, a P/E ratio of 17.89, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.82 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.11%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent analyst reports. Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Raymond James Financial lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday, April 14th. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 18th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.